Eli Lilly shares rose 2.34% to close at $1038.96 after Freedom Capital Markets upgraded the stock to Buy with a $1200 price target. The upgrade highlights the company's diversified growth and strong 2026 outlook following a significant Q4 earnings beat.
- The company has built a $1.5 billion stockpile of its weight-loss pill in preparation for a launch pending an FDA decision.
- Recent Q4 results showed revenue grew 43% to $19.3B, with the company issuing upbeat 2026 guidance of $80B–$83B.
- The stock outperformed the broader market and continued to rise in after-hours trading to $1042.00 (+0.29%).